<html>

<head>

<title>Stats: Number needed to treat (January 27, 2000)</title>

</head>

<body><!--start-->

<p><strong>Number Needed to Treat (created 2000-01-27).</strong></p>

<p>This page is moving to a <a href="http://new.pmean.com/what-is-nnt/">new website</a>.</p>

<p><em><font face="Times New Roman">Dear Professor Mean, How are patients and 
 their doctors supposed to decide whether a research finding has practical 
 significance? Why don't the medical journals make things clearer?</font></em></p>
<blockquote>
  <p><font face="Times New Roman">You're hoping for clarity from medical 
   profession? These are the folks who take a simple ear ache and call it &quot;otitis 
   media.&quot; To them, a runny nose is &quot;rhinorhea&quot; and a tummy ache is 
   &quot;gastrointestinal distress.&quot; It's enough to make me produce lacrimal 
   secretions.</font></p>
</blockquote>
<blockquote>
  <p><font face="Times New Roman">In fairness to these folks, though, they do 
   realize that practical interpretation of the medical research is difficult. 
   They are trying to change it. There are two important changes that we are 
   starting to see in medical research papers. First, they have learned that
   <strong>you can't ignore the size of the effect and focus only on the 
   statistical significance</strong>. Since confidence intervals provide 
   information about both the size and significance, many journals include them 
   instead of p-values.</font></p>
</blockquote>
<blockquote>
  <p><font face="Times New Roman">A second change is the realization that
   <strong>absolute changes in risk are more important than relative changes in 
   risk</strong>. A nurse recently informed me that my snoring (oops! sleep 
   apnea) can triple the risk of a stroke (excuse me, a cerebrovascular event) 
   if left untreated. But how serious is that for someone who is only 42 years 
   old and otherwise in good health? Three times nothing is nothing, and three 
   times something very small is still very small. I decided to get treatment, 
   but it was more for helping me and my wife to sleep better than a concern 
   about stroke.</font></p>
</blockquote>
<blockquote>
  <p><font face="Times New Roman">A good measure of the absolute risk is the<strong> 
   number needed to treat (NNT)</strong>. It is the average number of patients 
   that a doctor would need to treat in order to have one additional event 
   occur. A small value (e.g., NNT=2.7) means that a doctor will see a lot of 
   events in very little time. A large value (e.g., NNT=800) means that the 
   doctor will have to treat a large number of patients in order to see a very 
   few events.</font></p>
  <p><font face="Times New Roman">When you are measuring <b>an increase in bad 
   events like side effects that might be associated with a treatment</b>, then 
   the number needed to treat is sometimes described as the <b>number needed to 
   harm (NNH)</b>. Often you can quantify the tradeoffs between the benefits and 
   side effects of a treatment by comparing the NNT and NNH values.</font></p>
</blockquote>
<p><strong><font face="Times New Roman">Some examples</font></strong></p>
<blockquote>
  <p><font face="Times New Roman">Here are some examples of Numbers Needed to 
   Treat, found at the Bandolier web site (<a href="http://www.jr2.ox.ac.uk/bandolier/index.html">http://www.jr2.ox.ac.uk/bandolier/index.html</a>).
   </font></p>
  <p><font face="Times New Roman"><font color="#FF0000"><strong>Prevention of 
   post-operative vomiting using Droperidol, NNT=4.4</strong></font>. For every 
   four or five surgery patients treated with Droperidol, you will see one less 
   vomiting incident on average.</font></p>
  <p><font face="Times New Roman"><font color="#FF0000"><strong>Prevention of 
   infection from dog bites using antibiotics, NNT=16</strong></font>. For every 
   16 dog bites treated with antibiotics, you would see one fewer infection on 
   average.</font></p>
  <p><font face="Times New Roman"><font color="#FF0000"><strong>Primary 
   prevention of stroke using a daily low dose of aspirin for one year, NNT=102</strong></font>. 
   For every hundred patient years of treatment with aspirin, you will see one 
   fewer stroke on average.</font></p>
  <p><font face="Times New Roman">Notice that this <strong>last event is a rate</strong>.</font> 
   Assuming that the rates are reasonably homogenous over time,
   <font face="Times New Roman"><strong>one hundred patient years</strong> is 
   equivalent to <strong>following ten patients for a decade</strong>. Be 
   careful, of course, of rates that are not homogenous over time. If the rates 
   decline the longer you follow your patients, then the number of events you 
   will see for one hundred patients during their first year of therapy would be 
   quite different from the number of events you would see following ten 
   patients for their first decade of therapy.</font></p>
  <p><font face="Times New Roman">Here's another example from the British 
   Medical Journal (<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10381708&dopt=Abstract">Freemantle 
   1999: 318(7200); 1730-1737</a>). <font color="#FF0000"><b>Prevention of 
   cardiac death using beta blockers among patients with previous myocardial 
   infarction, NNT=42.</b></font> For every 42 patients treated for two years 
   with beta blockers, you would see one fewer death. This is superior to
   <font color="#FF0000"><b>treatment with antiplatelet agents (NNT=153), 
   Statins (NNT=94), or Warfarin (NNT=63)</b></font>, but not as effective as <b>
   <font color="#FF0000">thrombolysis and aspirin for 4 weeks (NNT=24)</font></b>.</font></p>
</blockquote>
<p><strong><font face="Times New Roman">Computational Example</font></strong></p>
<blockquote>
  <p><font face="Times New Roman">To compute the NNT, you need to <strong>
   subtract the rate in the treatment group from the rate in the control group 
   and then invert it</strong> (divide the difference into 1).</font></p>
  <p><font face="Times New Roman">A recently published article on the flu 
   vaccine showed that <font color="#FF0000"><strong>among the children who 
   received a placebo, 17.9% later had culture confirmed influenza</strong></font>. 
   In the <font color="#FF0000"><strong>vaccine group, the rate was only 1.3%</strong></font>. 
   This is a <font color="#FF0000"><strong>16.6% absolute difference</strong></font>. 
   When you invert this percentage, you get <font color="#FF0000"><strong>NNT=6</strong></font>. 
   This means that <font color="#FF0000"><strong>for every six kids who get the 
   vaccine, you will see one less case of flu on average</strong></font>.</font></p>
  <p><font face="Times New Roman">The study also looked at the rate of side 
   effects. In the <font color="#FF0000"><strong>vaccine group, 1.9% developed a 
   fever</strong></font>. Only <font color="#FF0000"><strong>0.8% of the 
   controls developed a fever</strong></font>. This is an absolute difference of 
   1.1%. When you invert this percentage, you get <font color="#FF0000"><strong>
   NNH=90</strong></font>. This means that <font color="#FF0000"><strong>for 
   every 90 kids who get the vaccine, you will see one additional fever on 
   average</strong></font>.</font></p>
  <p><font face="Times New Roman">Sometimes the <strong>ratio between NNT and 
   NNH</strong> can prove informative. For this study, <font color="#FF0000">
   <strong>NNH/NNT=90/6=15</strong></font>. This tells you that you should
   <font color="#FF0000"><strong>expect to see one additional fever for every 
   fifteen cases of flu prevented</strong></font>.</font></p>
  <p><font face="Times New Roman">Although I am not a medical expert, the 
   vaccine looks very promising because <strong>you can prevent a lot of flu 
   events and only have to put up with a few additional fevers</strong>. In 
   general, it takes medical judgment to assess the trade-offs between the 
   benefits of a treatment and its side effects. The NNT and NNH calculations 
   allow you to assess there trade-offs.</font></p>
</blockquote>
<p><b><font face="Times New Roman">What if the outcome measure is continuous?</font></b></p>
<blockquote>
  <p><font face="Times New Roman">To calculate the NNT or NNH, you need to have 
   a <b>distinct event</b>. With a continuous variable, you could define such an 
   event by <b>setting a cut-off</b>. For example, an intervention to improve 
   breastfeeding rates might improve the <font color="#FF0000"><b>average 
   duration of breastfeeding by seven weeks</b></font>. How would you calculate 
   the NNT for this data? Well, you might declare that you are interested in the 
   proportion of mothers who breastfeed for at least 12 weeks. If you had access 
   to the original data, you would find that <font color="#FF0000"><b>54% of 
   women in the control group and 87% in the treatment group breastfed for at 
   least 12 weeks</b></font>. This would allow you to compute an
   <font color="#FF0000"><b>NNT of 3</b></font>. For every three mothers given 
   the new intervention, one additional mother would breastfeed beyond 12 weeks.</font></p>
  <p><font face="Times New Roman">The choice of 12 weeks is somewhat arbitrary 
   and <b>you would get different results if you chose a different cut-off, such 
   as 24 weeks</b>. You should <b>choose a value that has clinical relevance</b> 
   to your colleagues.</font></p>
  <p><font face="Times New Roman">Calculating the NNT or NNH from a continuous 
   measure using a cutoff is usually impossible to do after the fact. <b>So if 
   you are reading someone else's work and they present the data as a mean 
   difference, you cannot calculate NNT or NNH.</b> You would need additional 
   information, such as the proportions that exceed some threshold, or you would 
   have to make some questionable assumptions, such as normality for the outcome 
   measure.</font></p>
</blockquote>
<p><strong><font face="Times New Roman">Summary</font></strong></p>
<blockquote>
  <p>Professor Mean explains that the journals are getting better at presenting 
   the practical implications of the research. In particular, they are 
   presenting the number needed to treat, a measure that helps you better 
   understand the practical significance of your research findings. <strong>The 
   number needed to treat is the average number of patients that you will have 
   to treat with a new therapy to see one additional success, on average, 
   compared to the standard therapy</strong>.</p>
</blockquote>
<p><strong><font face="Times New Roman">Further Reading</font></strong></p>
<ol>
  <li><strong><a href="http://members.aol.com/johnp71/ctab2x2.html">2-way 
  Contingency Table Analysis</a></strong>. John C. Pezzullo. Accessed on 
  2003-08-11. members.aol.com/johnp71/ctab2x2.html</li>
  <li><b>Adjusting the number needed to treat: incorporating adjustments for the 
  utility and timing of benefits and harms.</b> R Riegelman, WS Schroth. Medical 
  Decision Making 1993: 13(3); 247-52.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8412555&dopt=Abstract">
  [Medline]</a> </li>
  <li><b>Applying evidence to the individual patient.</b> S. E. Straus, D. L. 
  Sackett. Ann Oncol 1999: 10(1); 29-32.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10076718&dopt=Abstract">
  [Medline]</a> </li>
  <li><b>Basic statistics for clinicians: 3. Assessing the effects of treatment: 
  measures of association [published erratum appears in Can Med Assoc J 1995 Mar 
  15; 152(6):813].</b> R. Jaeschke, G. Guyatt, H. Shannon, S. Walter, D. Cook, 
  N. Heddle. Cmaj 1995: 152(3); 351-7.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7828099&dopt=Abstract">
  [Medline]</a>
  <a href="http://collection.nlc-bnc.ca/100/201/300/cdn_medical_association/cmaj/vol-152/0351.htm">
  [Full text]</a> </li>
  <li><b>Benefit-Risk ratios in the assessment of the clinical evidence of a new 
  therapy.</b> AR Willan, BJ O'Brien, DJ Cook. Cont Clin Trials 1997: 18(2); 
  121-30.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9129856&dopt=Abstract">
  [Medline]</a> </li>
  <li><b>Beta blockade after myocardial infarction: systematic review and meta 
  regression analysis.</b> Nick Freemantle, J Cleland, P Young, J Mason, J 
  Harrison. British Medical Journal 1999: 318(7200); 1730-1737.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10381708&dopt=Abstract">
  [Medline]</a>
  <a href="http://bmj.bmjjournals.com/cgi/content/abstract/318/7200/1730">
  [Abstract]</a>
  <a href="http://bmj.bmjjournals.com/cgi/content/full/318/7200/1730">[Full 
  text]</a> <a href="http://bmj.bmjjournals.com/cgi/reprint/318/7200/1730.pdf">
  [PDF]</a></li>
  <li><strong>
  <a href="http://www.jr2.ox.ac.uk/bandolier/Extraforbando/NNTextra.pdf">
  Calculating and Using NNTs</a></strong>. Bandolier. Accessed on 2003-06-12. 
  www.jr2.ox.ac.uk/bandolier/Extraforbando/NNTextra.pdf</li>
  <li><b>Calculating confidence intervals for the number needed to treat.</b> R. 
  Bender. Controlled Clinical Trials 2001: 22(2); 102-10.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11306148&dopt=Abstract">
  [Medline]</a> </li>
  <li><b>Calculating the &quot;number needed to be exposed&quot; with adjustment for 
  confounding variables in epidemiological studies.</b> R Bender, M Blettner. 
  Journal of Clinical Epidemiology 2002: 55(5); 525-530.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12007557&dopt=Abstract">
  [Medline]</a>
  <a href="http://wwwhomes.uni-bielefeld.de/rbender/PDF/nne_adj.pdf">[PDF]</a></li>
  <li><b>Calculating the number needed to treat for trials where the outcome is 
  time to an event.</b> D. G. Altman, P. K. Andersen. British Medical Journal 
  1999: 319(7223); 1492-5.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10582940&dopt=Abstract">
  [Medline]</a> <a href="http://bmj.com/cgi/content/full/319/7223/1492">[Full 
  text]</a> <a href="http://bmj.com/cgi/reprint/319/7223/1492.pdf">[PDF]</a></li>
  <li><b>Choice of Effect Measure for Epidemiological Data.</b> SD Walter. 
  Journal of Clinical Epidemiology 2000: 53(9); 931-939.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11004419&dopt=Abstract">
  [Medline]</a> </li>
  <li><b>Confidence limits made easy: interval estimation using a substitution 
  method.</b> L. E. Daly. Am J Epidemiol 1998: 147(8); 783-90.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9554420&dopt=Abstract">
  [Medline]</a> </li>
  <li><b>Events per person per year -- a dubious concept.</b> J Windeler, S 
  Lange. BMJ 1995: 310(6977); 454-56.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7873955&dopt=Abstract">
  [Medline]</a> <a href="http://bmj.com/cgi/content/full/310/6977/454">[Full 
  text]</a> </li>
  <li><b>Expressing the magnitude of adverse effects in case-control studies: 
  &quot;the number of patients needed to be treated for one additional patient to be 
  harmed&quot;.</b> L. M. Bjerre, J. LeLorier. British Medical Journal 2000: 
  320(7233); 503-6.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10678870&dopt=Abstract">
  [Medline]</a> <a href="http://bmj.com/cgi/content/full/320/7233/503">[Full 
  text]</a> <a href="http://bmj.com/cgi/reprint/320/7233/503.pdf">[PDF]</a></li>
  <li><strong><a href="http://www.jr2.ox.ac.uk/bandolier/band36/b36-2.html">
  Getting NNTs</a></strong>. Bandolier. Accessed on 2003-07-01. 
  www.jr2.ox.ac.uk/bandolier/band36/b36-2.html</li>
  <li><b>Influence of method of reporting study results on decision of 
  physicians to prescribe drugs to lower cholesterol concentration.</b> H. C. 
  Bucher, M. Weinbacher, K. Gyr. British Medical Journal 1994: 309(6957); 761-4.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7950558&dopt=Abstract">
  [Medline]</a> <a href="http://bmj.com/cgi/content/abstract/309/6957/761">
  [Abstract]</a> <a href="http://bmj.com/cgi/content/full/309/6957/761">[Full 
  text]</a> </li>
  <li><b>Interpreting the Number Needed to Treat.</b> Lambert A. Wu, Thomas E. 
  Kottke. Journal of the American Medical Association 2002: 288(7); 830-1.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12186595&dopt=Abstract">
  [Medline]</a> </li>
  <li><b>Missing the point (estimate)? Confidence intervals for the number 
  needed to treat.</b> N. J. Barrowman. Cmaj 2002: 166(13); 1676-7.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12126323&dopt=Abstract">
  [Medline]</a> <a href="http://www.cmaj.ca/cgi/content/full/166/13/1676">[Full 
  text]</a> <a href="http://www.cmaj.ca/cgi/reprint/166/13/1676.pdf">[PDF]</a></li>
  <li><b>Nicotine nasal spray with nicotine patch for smoking cessation: 
  randomised trial with six year follow up.</b> T. Blondal, L. J. Gudmundsson, 
  I. Olafsdottir, G. Gustavsson, A. Westin. British Medical Journal 1999: 
  318(7179); 285-8.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9924052&dopt=Abstract">
  [Medline]</a> <a href="http://bmj.com/cgi/content/abstract/318/7179/285">
  [Abstract]</a> <a href="http://bmj.com/cgi/content/full/318/7179/285">[Full 
  text]</a> <a href="http://bmj.com/cgi/reprint/318/7179/285.pdf">[PDF]</a></li>
  <li><b>Number needed to harm should be measured for treatments.</b> Arnold 
  Zermansky. British Medical Journal 1998: 317(7164); 1014.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9765180&dopt=Abstract">
  [Medline]</a> <a href="http://bmj.com/cgi/content/full/317/7164/1014">[Full 
  text]</a> </li>
  <li><b>Number needed to screen: development of a statistic for disease 
  screening.</b> C. M. Rembold. British Medical Journal 1998: 317(7154); 307-12.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9685274&dopt=Abstract">
  [Medline]</a> <a href="http://bmj.com/cgi/content/abstract/317/7154/307">
  [Abstract]</a> <a href="http://bmj.com/cgi/content/full/317/7154/307">[Full 
  text]</a> <a href="http://bmj.com/cgi/reprint/317/7154/307.pdf">[PDF]</a></li>
  <li><b>The number needed to treat: a clinically useful measure of treatment 
  effect.</b> R. J. Cook, D. L. Sackett. British Medical Journal 1995: 
  310(6977); 452-4.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7873954&dopt=Abstract">
  [Medline]</a> <a href="http://bmj.com/cgi/content/full/310/6977/452">[Full 
  text]</a> </li>
  <li><b>Number needed to treat: Caveat emptor.</b> LA Wu, TE Kottke. Journal of 
  Clinical Epidemiology 2001: 54(2); 111-116.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11166524&dopt=Abstract">
  [Medline]</a> </li>
  <li><b>Numbers needed to treat derived from meta-analysis.</b> Bruce G. 
  Charlton. British Medical Journal 1999: 319(7218); 1199.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10541527&dopt=Abstract">
  [Medline]</a>
  <a href="http://bmj.bmjjournals.com/cgi/content/full/319/7218/1199/a">[Full 
  text]</a> </li>
  <li><b>Randomised controlled trial shows that glyceryl trinitrate heals anal 
  fissures, higher doses are not more effective, and there is a high recurrence 
  rate.</b> EA Carapeti, MA Kamm, PJ McDonald, SJ Chadwick, D Melville, RK 
  Phillips. Gut 1999: 44(5); 727-30.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10205213&dopt=Abstract">
  [Medline]</a>
  <a href="http://gut.bmjjournals.com/cgi/content/abstract/44/5/727">[Abstract]</a>
  </li>
  <li><b>Recombinant or urinary follicle-stimulating hormone? A 
  cost-effectiveness analysis derived by particularizing the number needed to 
  treat from a published meta-analysis.</b> B. Ola, S. Papaioannou, M. A. Afnan, 
  N. Hammadieh, S. Gimba. Fertil Steril 2001: 75(6); 1106-10.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11384634&dopt=Abstract">
  [Medline]</a> </li>
  <li><b>Unqualified success and unmitigated failure: 
  number-needed-to-treat-related concepts for assessing treatment efficacy in 
  the presence of treatment-induced adverse events.</b> M Schulzer, GB Mancini. 
  International Journal of Epidemiology 1996: 25(4); 704-12.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8921446&dopt=Abstract">
  [Medline]</a> </li>
  <li><b>Updated New Zealand cardiovascular disease risk-benefit prediction 
  guide.</b> R. Jackson. Bmj 2000: 320(7236); 709-10.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10710588&dopt=Abstract">
  [Medline]</a>
  <a href="http://bmj.bmjjournals.com/cgi/content/full/320/7236/709">[Full text]</a>
  <a href="http://bmj.bmjjournals.com/cgi/reprint/320/7236/709.pdf">[PDF]</a></li>
  <li><b>Using numerical results from systematic reviews in clinical practice.</b> 
  H. J. McQuay, R. A. Moore. Ann Intern Med 1997: 126(9); 712-20.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9139558&dopt=Abstract">
  [Medline]</a> </li>
  <li><b>When should an effective treatment be used? Derivation of the threshold 
  number needed to treat and the minimum event rate for treatment.</b> J. C. 
  Sinclair, R. J. Cook, G. H. Guyatt, S. G. Pauker, D. J. Cook. J Clin Epidemiol 
  2001: 54(3); 253-62.
  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11223323&dopt=Abstract">
  [Medline]</a></li>
</ol>
<p><b>Additional references that I need to add to my bibliography</b></p>
<ol>
  <li>BMJ 1999;318:1548-1551 ( 5 June )
  <a href="http://bmj.bmjjournals.com/cgi/content/full/318/7197/1548">
  http://bmj.bmjjournals.com/cgi/content/full/318/7197/1548</a></li>
  <li>J Clin Epidemiol. 2002 Jan;55(1):102-3. PMID: 11781128.</li>
  <li>JAMA. 2002 Jun 5;287(21):2813-4. PMID: 12038920</li>
</ol>

</body>

</html>
